A new malaria vaccine will soon enter the experimental phase. This vaccine, which is being developed by the American Pharmaceutical firm Sanaria, will attack the sporozoites and its first phase is expected to begin in January 2014 in Malabo - Equatorial Guinea. The CEO of Sanaria, Dr. Steve Hoffman alongside his entomologist was in Malabo to discuss the feasibility of experimenting this with the health authorities of Equatorial Guinea. He was advised that for this to happen, the ethics committee and the National Regulatory Authority must approve the protocol. During the different meetings that took place in Malabo to which CARN was invited, many questions were asked the firm managers especially as concerns its guarantee, efficiency, the innocuity as well as the cost of the vaccine. The ethics committee and the national regulatory authority will be assisted technically by the WHO AFRO IST and some local experts. The Schweitzer research center in Lambéré Gabon will also contribute with its practical expertise in the implementation of this type of research meanwhile Dr Salim Abdullah of Ifakara in Tanzania will be the principal investigator. A scientific committee will also be put in place. Other participants who took part with a lot of interest at the series of meetings were the Ministry of Mines, Marathon Oil, EGLING gas Production Company, the NGO MCDI, the University of Equatorial Guinea, the La Paz ultra modern Clinic, the National Malaria Control Program and WHO.